Kornimate/medical-research-clean huggingface dataset:
rescue quadratus lumborum blocks for post-cesarean pain

Conditions: Morphine; Analgesics; Analgesics, Opioid; Peripheral Nervous System Agents

Summary: the purpose of this study is to assess whether quadratus lumborum (ql) block performed 1 day after cesarean delivery will provide supplemental post-cesarean analgesia and reduce opioid requirements.


Eligibility criteria:
inclusion criteria: * elective or non-elective cesarean delivery on prior day * pain scores \>5/10 exclusion criteria: * bmi \>40 * obstructive sleep apnea * drug abuse * chronic pain * chronic opioid use * abdominal surgeries other than cesarean delivery * contraindications to neuraxial or regional anesthesia * received general anesthesia or did not receive neuraxial morphine for cesarean delivery

Keywords: quadratus lumborum block bupivacaine cesarean delivery c-section intrathecal morphine post-operative pain post-cesarean analgesia
treatment of age-related macular degeneration with anecortave acetate

Conditions: Macular Degeneration

Summary: the purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control classic neovascularization following failure of treatment with photodynamic therapy using visudyne.


Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of patients that previously had a failure of treatment with photodynamic therapy using visudyne. 2. patients must be at least 50 years of age. 3. visual acuity of 20/30 to 20/320 in study eye on the early treatment of diabetic retinopathy study (etdrs) visual acuity chart 4. visual acuity of 20/800 or better in fellow eye on the etdrs visual acuity chart exclusion criteria: 1. patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions. 2. patients who have undergone intraocular surgery within the last 2 months. 3. patient participating in any other investigational drug study. 4. use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication. 5. inability to obtain photographs to document choroidal neovascularization (cnv) (including difficulty with venous access). 6. patient with significant liver disease or uremia. 7. patient with known adverse reaction to fluorescein and indocyanine green or iodine. 8. patient has a history of any medical condition which would preclude scheduled visits or completion of study 9. patient has had insertion of scleral buckle in the study eye 10. patient has received radiation treatment 11. patient is on anticoagulant therapy with the exception of aspirin 12. patient is pregnant or nursing.

Keywords: age-related macular degeneration
intra-erythrocyte dexamethasone sodium phosphate in ataxia teleangiectasia patients

Conditions: Nervous System Disorder; Genetic Syndrome

Summary: the study has the aim to evaluate the improvement in cns symptoms measured by international co-operative ataxia rating scale (icars) in patients with ataxia teleangectasia (at), during a period of treatment with ery-dex (dexamethasone sodium phosphate ex vivo encapsulated into human autologous erythrocytes).

this is a multi-centre, single arm, open label, 6 months, phase ii study to evaluate the effect of ery-dex in improving central nervous system (cns) symptoms in patients with ataxia teleangectasia (at). the study consists of a screening period (max duration of 30 days) and a treatment period (duration 6 months).

Eligibility criteria:
inclusion criteria: * neurological signs of at * patients in autonomous gait or helped by a support * proven molecular diagnosis of at * males and females aged \> 3 years * body weight \>15 kg * plasma levels of lymphocytes cd4+/mm3 \> 500 (for patients aged 3-6 years) or \> 200 (older than 6 years) * written ic to participate. exclusion criteria: * current or previous neoplastic disease * history of severe impairment of the immunological system * chronic conditions representing a contraindication to the use of steroid drugs * non compliance with the study request * any previous steroid assumption within 30 days before starting ery-dex * have any other significant disease that in the investigator's opinion would exclude the patient from the trial * females of childbearing potential who were pregnant, breast-feeding or were not using adequate contraceptive methods

Keywords: ataxia teleangiectasia at ery-dex dexamethasone dexamethasone sodium phosphate
ultrasonography guided subacromial sodium hyaluronate injection in rotator cuff disease

Conditions: Subacromial Impingement Syndrome

Summary: this study will be performed to examine the effect of ultrasound-guided subacromial sodium hyaluronate injection in patients with impingement syndrome without rotator cuff complete tear.

rotator cuff disease in particular is a common cause of shoulder pain and weakness and comprises a significant proportion of the musculoskeletal complaints presenting to primary care doctors. ultrasound is a readily available and cheap modality for looking more specifically at the rotator cuff and surrounding structures. more recently, ultrasound guidance has become a commonly employed method to perform diagnostic or therapeutic interventions. despite the long history and the fact that this is a common diagnosis made in clinical practice, the exact cause and best treatment for this condition still are being explored. although there are a few high-quality studies demonstrating the efficacy of sodium hyaluronate injection for rotator cuff disease, this study will be performed to examine the effect of ultrasound-guided subacromial sodium hyaluronate injection in patients with impingement syndrome without rotator cuff complete tear.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * subacromial impingement syndrome * without a complete tear of rotator cuff * willingness to participate exclusion criteria: * had any rheumatic disease, glenohumeral osteoarthritis, full-thickness rotator cuff tears, fractures, diabetes mellitus, infections, or tumors. * had hypersensitivity to hyaluronate * had participated in any other study within 6 months * had received a subacromial injection within 8 weeks * were pregnant or planned to become pregnant * were at risk of complications of intra-articular injections such as patients who received anti-coagulant drugs.
clinical utility of circulating tumor dna in gastro-esophageal cancer

Conditions: Esophageal Cancer; Gastric Cancer

Summary: this is a prospective cohort study designed to evaluate the treatment effect as well as predictive and prognostic factors with special emphasis on the clinical utility of ctdna in plasma in patients with gastroesophageal cancer. patients with gastroesophageal cancer are included in 5 separate cohorts scheduled for * surgical resection + perioperative chemotherapy (cohort 1) * neoadjuvant chemoradiotherapy followed by surgical resection (cohort 2) * definitive chemoradiotherapy with curative intent (cohort 3) * systemic therapy with the intent to prolong survival (cohort 4) * palliative treatment without the use of chemotherapy (cohort 5)


Eligibility criteria:
inclusion criteria: gastroesophageal cancer age 18 years or older able to understand and sign written informed consent exclusion criteria: patients not providing informed consent

Keywords: circulating tumor dna
antimicrobial resistance (amr) study

Conditions: Anti-Microbial Resistance

Summary: this study aims to investigate the knowledge, attitudes and behaviours of the antibiotic resistance and prudent antibiotic use among healthcare workers in syria

this will be a multicenter cross-sectional study across the country. the online questionnaire will be conducted in different governorates and published online through social media. an online link to the web-based questionnaire will be developed using google forms; it was self-designed based on questions used in previous similar studies\[1\]-\[5\].the questionnaire will take about 5-10 minutes to be completed by each participant. the questionnaire consists of eight sections. all participants fulfilling the inclusion criteria will be invited to participate. snowball sampling will select the study participants with a confidence level of 95% and a margin of error of 5%. the lower limit of participants should be included is 200 healthcare workers. the questionnaire will be pre-tested on a small sample of participants to confirm the practicability and clarity of questions to check the content. observations of the pilot study will not be included in the final analysis. responses will be downloaded from google form as an excel sheet, and data will be analyzed using spss version 28.

Eligibility criteria:
inclusion criteria: we include healthcare workers, males or females aged 25 to over 65. - exclusion criteria: participants who do not agree to fill the questionnaire, who do not agree to fill all requested questions, and who filled the questionnaire before. -

Keywords: antibiotics resistance knowledge
the effects of the use of virgin mary herb in childbirth

Conditions: Pain During Labour; Fear of Childbirth

Summary: this is a study to see if the use of virgin mary herb during birth has an effect on fear, pain and duration during birth. virgin mary herb is a dry plant and it is believed that when added to water during birth, it makes birth easier.

objective: midwives mostly develop nonpharmacological methods to cope with fear and pain management during birth in order not to interfere with the flow of birth. there are limited studies on traditional birth methods in turkey. the aim of this study is to examine the effect of the use of the virgin mary herb, one of the traditional methods applied during birth, on fear of birth and pain felt during birth. material and method: the universe of the study consists of all pregnant women who were admitted to the birth unit of a city hospital in istanbul between march 2023 and december 2023. a power analysis was conducted to determine the number of people to be included in the study sample. the power of the test was calculated with the g\*power 3.1 program. in order to exceed the 95% value in determining the power of the study; a total of 84 people, 42 people in groups, should be reached at a significance level of 5% and an effect size of 0.732 (df=82; t=1.66). the study aimed to reach a total of 100 people, with the condition of including 50 people in each group, considering the high power of the test and the losses. data were collected between september 5, 2024 and december 31, 2024. 50 intervention groups and 50 control groups were included in the study, and all pregnant women received midwifery care. the intervention group was additionally shown the opening of the virgin mary herb in water.

Eligibility criteria:
inclusion criteria: * being over 18 years old, * being able to understand and speak turkish, * being primiparous, * not having a chronic disease, * having completed the 37th week of pregnancy, * not having passed the 42nd week of pregnancy, * being in a cephalic presentation, * having reached 4cm cervical dilatation, exclusion criteria: * multiparous pregnancy, * application of labor induction, * being a high-risk pregnancy, * having received childbirth preparation training, * being an immigrant, * use of non-pharmacological methods other than virgin mary

Keywords: anastatica hierochuntica
a study to describe the diagnosis, anti-cancer treatment and clinical outcome in patients with newly diagnosed breast cancer in latin america

Conditions: Breast Cancer

Summary: a prospective, multicenter, non-interventional study of primary data collection, designed to describe the diagnosis, anti-cancer treatment and clinical outcomes in patients with breast cancer in latin america.


Eligibility criteria:
inclusion criteria: * histological confirmed newly diagnosed stage i to iv (recurrent or de novo) breast cancer no more than 12 months prior to site activation, although they can have received anti-cancer treatment during that time exclusion criteria: * patients not receiving treatment for breast cancer with national approved drugs according to standard of care and in line with the current summary of product characteristics (spc) /local labeling * patients not receiving the roche studied medicinal product, but a biosimilar
a phase iii second line trial in advanced pancreatic cancer conko 003

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to compare best supportive care plus oxaliplatin/ folinic acid/ 5-fu versus best supportive alone in patients with gemcitabine refractory pancreatic cancer.

gemcitabine (g) given until progressive disease (pd) is still standard therapy in patients with advanced pancreatic cancer. no standard secondline regimen is available after pd. best supportive care (bsc) is the main option for these patients. our phase ii study (pelzer et al, asco 2002) showed activity of the off (oxaliplatin/folinic acid/5-fu) regimen. to confirm these data we started this multicenter phase iii study to examine off vs. bsc alone. 165 patients were needed for this study. following ct/ mrt confirmed pd patients were randomized. stratification included duration of firstline therapy, karnofsky performance status (kps) and tumor stage. off (outpatient regimen): 5-fu 2g/m² (24h)/fa 200 mg/m² (30min) on d1, d8, d15, d22, additional oxaliplatin 85mg/m² (2h) on day 8 and 22. rest on day 23 and 42.

Eligibility criteria:
inclusion criteria: * patients with histologically or cytologically confirmed metastatic pancreatic adenocarcinoma that had progressed during first line gemcitabine therapy were eligible for inclusion in the study. other inclusion criteria were: * age \> 18 years * karnofsky performance status \> 70% * bidimensionally measurable reference lesion, adequate laboratory values for hematology (white blood cell \[wbc\] count \> 3.5´109/l, platelet count \> 100´109/l), renal function (creatine clearance \> 30 ml/min) and hepatic function (aspartate aminotransferase \[ast\] or alanine aminotransferase \[alt\] \< 2.5 ´ upper normal limit \[unl\] and in the case of liver metastasis \< 5 x unl) * as well as controlled pain exclusion criteria: * patients were excluded from the study if they had any severe concurrent medical condition interfering with planned therapy, serious cardiac disease, sensory/ motor neuropathy \> grade 2 or had previous or current malignancies at other origin; besides, pregnant or lactating women were excluded. * all patients provided written informed consent.

Keywords: refractory pancreatic cancer gemcitabine phase iii second line
deep bite correction using auxiliary intrusion cantilevers with initial archwires in adolescents

Conditions: Deep Overbite

Summary: the purpose of this study was to determine the effect of auxiliary intrusion cantilevers used with resilient archwires during the leveling and alignment phase in intruding lower incisors.


Eligibility criteria:
inclusion criteria: * permanent dentition present except for third molars * no history of previous orthodontic treatment. * class i or ii malocclusion with minimal or no lower anterior crowding (\<3 mm) * excessive overbite (\>3 mm). exclusion criteria: * syndromic patients as well as individuals with skeletal asymmetry * endodontically treated or periodontally involved loweranterior teeth. * need for tooth extraction in the lower arch. * agenesis (except for third molars) * any kind of tooth/root shape anomaly
quality of life and long-term outcomes after hospitalization for covid-19

Conditions: Quality of Life; Long-term Outcomes; Coronavirus Infection

Summary: the present study aims to assess the determinants of health-related quality of life and long-term outcomes among survivors of hospitalization for covid-19 in brazil. the investigators will conduct a multicenter prospective cohort study nested in randomized clinical trials (coalition covid-19 brazil initiative) originally designed to assess the effects of specific covid-19 treatments. adult survivors of hospitalization due to proven or suspected sars-cov-2 infection will be followed up for a period of one year by means of structured telephone interviews. the primary outcome is one-year health-related quality of life assessed by the eq-5d-3l. secondary outcomes include all-cause mortality, rehospitalizations, return to work or study, physical functional status assessed by the lawton \& brody instrumental activities of daily living scale, dyspnea assessed by the modified medical research council dyspnea scale, need of long-term ventilatory support, symptoms of anxiety and depression assessed by the hospital anxiety and depression scale, and symptoms of posttraumatic stress disorder assessed by the impact of event scale-revised.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and older * hospitalization due to proven or suspected sars-cov-2 infection * meeting eligibility criteria for coalition covid-19 brazil randomized clinical trials exclusion criteria: * death during the hospitalization * absence of telephone contact * absence of proxy for patients with communication difficulties * refusal or withdrawal of agreement to participate
comparative analysis between sleeve gastrectomy and roux-en y gastric bypass in bariatric operation

Conditions: Obesity, Morbid; Overnutrition; Nutrition Disorders; Overweight and Obesity; Body Weight Changes

Summary: prospective, double-arm, multi-center cohort study on obese patients, for laparoscopic sleeve gastrectomy versus roux-en y gastric bypass

this is prospective cohort study. total 400 obese patients will be enrolled(sleeve gastrectomy 200 patients, roux-en-y gastric bypass 200) the principal investigator or another clinical investigator in charge will individually inform the patients about the study, before operation at out patient clinic. at that time patient is selected to either sleeve gastrectomy group or roux-en-y gastric bypass group. all investigator report to clinical research center about patients bmi and operation method. about 30-35 obesity patients will be enrolled according to their bmi status. patients' bmi status is classified into several parts by 2.5 gap started from 27.5. all patients will undergo periodically anthropometry, laboratory tests, bioelectrical impedance analysis, gastrofiberscopy, polysomnography and abdomen ct before and after surgery. patients with hypertension will undergo echocardiography. patients with polycystic ovary syndrome will be checked hormonal study. patients with type 2 diabetes mellitus will be performed 75g oral glucose tolerance test test. surgical complication include wound morbidities, gastrointestinal leakage or fistula, postoperative bleeding, intra-abdominal abscess, stricture , adhesive ileus, reflux esophagitis, marginal ulceration, dumping syndrome and internal hernia. systemic complication which is not associated with the operation field include ling morbidities, heart morbidities, urinary morbidities and others. hospital mortality is defined as postoperative death form any cause within 30 days after operation. all patients will be followed up post operative 1 month, 3 month, 6 month, 12 month, 18 month, 24 month. all patients' liver tissue, visceral fat and subcutaneous fat will be harvested during operation. all patients' blood sample will be collected at out patient clinic visit. all patients' urine and face will be collected at out patient clinic visit and will be analyzed to evaluate microbial change throughout pre and post operation period.

Eligibility criteria:
inclusion criteria: * obesity patients(bmi over 35) * morbid obesity patients(bmi over 30) with cardiovascular disease, hypertension, hyperlipidemia, type 2 diabetes mellitus, obstructive sleep apnea * type 2 diabetes mellitus obesity patients(bmi over 27.5) who were treated medical therapy or hba1c level over 7% exclusion criteria: * patients who underwent previously bariatric operation * patients who were diagnosed malignant disease patients within 5 years * patients who were involved with other clinical trial within 3 months * patients who are risky to conduct general anesthesia for operation

Keywords: primary bariatric surgery morbid obesity sleeve gastrectomy roux-en y gastric bypass south korea
effect of a prebiotic on colic and crying and fussing behaviour in infants

Conditions: Colic

Summary: colic, or inconsolable crying and fussing, affects around 20% of babies who are 3 months of age or younger. to date, there are no known treatments that have been found to help reduce colic and its symptoms in babies. the investigators would like to see whether a baby formula that contains a prebiotic will lead to the same improvements in babies with colic. the investigators will test this by giving some babies a formula with the prebiotic and other babies a placebo formula.


Eligibility criteria:
inclusion criteria: * healthy, term infant from a singleton birth (=\>37 weeks gestational age); formula fed; primary caregiver able to read and write in english; current colicky behaviour exclusion criteria: * infants with known genetic syndromes; birth weight (\<2500g); use of proton pump inhibitors; use of antibiotics in previous week; use of nutritional colic remedies; use of probiotics; maternal medical history of diabetes (excluding gestational diabetes), tuberculosis, or any perinatal infection while pregnant with child enrolled in study; presence of blood in infant stool sample; possible cow milk protein allergy
excisional vacuum-assisted breast biopsy

Conditions: Atypical Ductal Hyperplasia; Ductal Carcinoma in Situ

Summary: the goal of this prospective cohort study is to evaluate the possibility of vacuum-assisted excisional biopsy (vae) to completely remove the pathology in case of small lesions for atypical ductal hyperplasia (adh) and low-intermediate grade ductal carcinoma in situ (dcis).

surgery is the current standard of care of breast lesions like the ductal carcinoma in situ (dcis) and the atypical ductal hyperplasia (adh). however, the survival benefit of surgical resection in patients with such lesions appears to be low, especially for adh and low-grade dcis where comorbidity of surgery and prior depression have been reported as important factors related to worse quality of life in these women. patients with suspicious breast lesions (birads\>3) who are candidates for vacuum assisted breast biopsy will be prospectively select and enroll if the radiological lesion diameter is less than 15 mm. the investigators will select those patients in whom after an initial sequence of sampling (12 cores), and will check the complete macroscopic removal of the lesion (with radiograms of the biopsied part of the breast). those patients (complete macroscopic removal, with real-time verification during the procedure) will be randomized into two groups. a first group of patients will finish the biopsy procedure after the first collection sequence (12 cores, 3 grams of tissue taken and complete macroscopic removal). a second group of patients (randomized subdivision) will undergo a second sequence of biopsy samples (other 4 cores and 1 gram of tissue taken) in the same session: the material collected will be sent separately to the pathologist.

Eligibility criteria:
inclusion criteria: * patients with suspicious breast lesions (birads \>3) * patients with a lesion \<= of 15mm. * capable and willing to comply the specific informed consent form * patients with adh biopsy results or low intermediate-grade dcis * patients who will undergo surgery exclusion criteria: - patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study